Skip to main content
. 2018 May 17;9:233. doi: 10.3389/fendo.2018.00233

Figure 1.

Figure 1

Liraglutide attenuated glucose levels, body weight gain, and insulin resistance. (A) Fasting blood glucose (FBG) levels. (B) Postprandial blood glucose (PBG) levels. (C) Food intake. (D) Body weight. (E) Fasting insulin (FINS) levels. (F) Insulin sensitivity index (ISI). (G) The homeostatic model assessment-insulin resistance (HOMA-IR). Data are presented as the mean ± SEM. *P < 0.05 vs WN group; #P < 0.05 vs WL group; and &P < 0.05 vs GN group.